"Patients presenting with chronic diarrhea, blood in the stool, unexplained nausea and vomiting, or unexplained weight loss ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

And Arcutis Biotherapeutics announced approval of roflumilast (Zoryve) topical foam 0.3% for plaque psoriasis of the scalp ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

A new antibiotic that has the potential to save millions of lives has entered its last phase of human testing. Swiss ...

As the administration pushes for a return to US manufacturing, outsourcing agreements with domestic manufacturers are ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech for small-molecule monovalent glue medicine ...

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

BioNTech SE (Nasdaq: BNTX, "BioNTech” or "the Company”) will present clinical trial data from select pipeline candidates across the Company's diversified oncology portfolio at the American Society of ...